<rt id="hnmjw"></rt>
  1. <ruby id="hnmjw"><table id="hnmjw"></table></ruby>
  2. <source id="hnmjw"><optgroup id="hnmjw"></optgroup></source>
  3. <rt id="hnmjw"></rt>

    <rt id="hnmjw"><optgroup id="hnmjw"></optgroup></rt>
    <rp id="hnmjw"></rp><rp id="hnmjw"><meter id="hnmjw"></meter></rp>
  4. <strong id="hnmjw"></strong>

  5. <rp id="hnmjw"><meter id="hnmjw"></meter></rp>
  6. Researchers & Partners

    Our vision is to discover, develop and deliver transformational medicines for patients through our internal discovery efforts and innovative collaborations and strategic business development opportunities.

    What We're Focused On

    What We're Focused On

    We concentrate our research and development efforts on our core therapeutic areas, and are pursuing multiple drug platforms for each.
    In the Pipeline

    In The Pipeline

    View the entire pipeline or customize your search by area of disease, development phase or modality.

    Investigating Combinations in Cancer Research

    Investigating Combinations in Cancer Research


    Our Research & Development Team

    Our Research & Development Team

    Our people are dedicated to unlocking the potential of innovative science. Our curiosity, persistence and desire to solve complex problems allow us to pursue our goal of delivering transformational medicines to patients.
    Our Research and Development Facilities

    Our Research and Development Facilities

    Take a look at the worldwide network of state-of the-art facilities where our discovery and development work happens.


    Partnering

    Partnering

    We actively seek partners with access to cutting-edge science that complements the innovation coming out of our own labs. Our business development team collaborates with R&D and organizations around the world to develop transformational medicines.


    Researcher Resources

    Independent Research

    Independent Research

    Bristol-Myers Squibb wishes to advance science through supporting novel, independent research that addresses unmet need surrounding our products and therapeutic areas.

    Clinical Trials

    Clinical Trials

    In 2017, we invested $4.8 billion* in R&D which included the discovery and development of new medicines for patients.

    *This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.?

    Evan Janovitz

    Input at Every Stage of Discovery

    Evan Janovitz leads a team of veterinary pathologists and allied scientists in the Discovery Toxicology organization.
    天天影视网